Simple Summary Heat-shock proteins (HSPs) are molecular chaperones overexpressed in
tumor cells and are necessary for their survival. In leukemia and lymphoma, HSPs have …

Despite the rapid advancement in the introduction of new drugs for cancer therapy, the
frequent emergence of drug resistance leads to disease progression or tumor recurrence …

Cost-efficient library generation by early barcoding has been central in propelling single-cell
RNA sequencing. Here, we optimize and validate prime-seq, an early barcoding bulk RNA …

The establishment of cellular identity is driven by transcriptional and epigenetic regulators of
the chromatin proteome-the chromatome. Comprehensive analyses of the chromatome …

Somatic heterozygous mutations in the active site of the enhancer of zeste homolog 2
(EZH2) are prevalent in diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia …

AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment
outcome, especially in patients that are ineligible for intensive chemotherapy …

All-trans-retinoic acid (ATRA)-based differentiation therapy of acute promyelocytic leukemia
(APL) represents one of the most clinically effective examples of precision medicine and the …

Acute myeloid leukemia (AML) is a heterogenous and challenging hematological
malignancy with suboptimal outcomes. The implications of advanced technologies in the …

Epigenetic deregulation is now a well-recognized although not yet fully understood
mechanism that contributes to the development and progression of myeloid malignancies. In …

Simple Summary Therapeutic advances in acute myeloid leukemia (AML) are dependent on
identifying and targeting the molecular aberrations that drive disease. The European …